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44 The Journal of Thoracic and Cardiobjective: This study was undertaken to examine the outcomes of surgery for active
nfective endocarditis in a large cohort of patients.
ethods: Three hundred eighty-three consecutive patients underwent surgery for
ctive infective endocarditis. The mean age was 51  16 years, and 64% were men.
he infected valve was native in 266 patients and prosthetic in 117. Staphylococcus
ureus was the most common microorganism. Surgery consisted of valve replace-
ent or repair in patients with infection limited to the cusps or leaflets of the valve
r radical resection of seemingly infected paravalvular tissues, and reconstruction
ith patches and valve replacement in patients with abscess (135 patients). The
ean follow-up was 6.1  5.2 years.
esults: There were 45 (12%) operative and 88 (23%) late deaths. The operative
ortality did not change during the period of study. Preoperative shock, prosthetic
alve endocarditis, paravalvular abscess, and S aureus were independent predictors
f operative mortality. Age, shock, prosthetic valve endocarditis, left ventricular
jection fraction less than 40%, and recurrent endocarditis were independent pre-
ictors of death from all causes. Survivals at 15 years were 44% 5% overall, 59%
5% for native valve endocarditis, and 25% 7% for prosthetic valve endocarditis
P  .001). Freedom from recurrent endocarditis at 15 years was 86%  3% for all
atients, similar to those for native and prosthetic valve endocarditis (P  .39).
reedom from reoperation at 15 years was 70%  6% for all patients, similar to
hose for native and prosthetic valve endocarditis (P  .55).
onclusions: Surgery for endocarditis continues to be challenging and associated
ith high operative mortality and morbidity. Age, shock, prosthetic valve endocar-
itis, impaired ventricular function, and recurrent infections adversely affect long-
erm survival.
ppropriate antibiotic therapy is the most important component in the treat-
ment of patients with infective endocarditis.1 Depending on how promptly
the disease is diagnosed and appropriate antibiotics are started, on the
irulence of the microorganism, and on whether the infected valve is native or
rosthetic, surgery may become indispensable to save the patient’s life and eradicate
he infection. Timing of surgery is crucial for patients for whom medical therapy
ails. Delaying surgical treatment often increases the probability of complications
nd also operative mortality and morbidity. The notion that less virulent microor-
anisms, such as Streptococcus viridans, always respond to antibiotics alone is
rroneous, because these bacteria can cause extensive damage to a heart valve and
urrounding tissues if inadequately treated.2 Certain cases of infective endocarditis
re deemed inoperable because of multiorgan failure or extensive cerebral damage
rom septic emboli, and these patients die of the disease. This study is a retrospec-
ive review of our experience with surgery for active infective endocarditis.
vascular Surgery ● January 2007
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CDaterials and Methods
review of the cardiac surgery database of Toronto General
ospital disclosed 383 patients who underwent surgery for active
nfective endocarditis from 1978 to 2004. Because the database did
ot contain all pertinent information for this disease, the hospital
edical records were also reviewed to confirm the diagnosis and
he indications for operation and to identify the microorganisms.
he indications for surgery were one or more of the following
actors: cardiogenic or septic shock in 53 patients (14%), conges-
ive heart failure in 210 (55%), paravalvular abscess in 81 (21%),
ystemic or cerebral thromboembolism in 45 (12%), persistent
epsis in 72 (19%), and large vegetations in 39 (10%). Table 1
hows the clinical characteristics of the patients. Coronary angiog-
aphy was performed in most patients older than 50 years and in
hose with suspected coronary artery disease, unless they had large
egetations in the aortic root.
icroorganisms
nformation regarding the offending microorganism was available
or 329 patients: Staphylococcus aureus in 87 (23%), Staphylo-
occus epidermidis in 37 (10%), S viridans in 69 (18%), Entero-
occus faecalis in 21 (5%), other streptococci in 56 (15%), other
acteria in 35 (9%), fungal endocarditis in 1, and culture-negative
ndocarditis in 23 (6%).
perative Procedures
he infection was limited to the cusps or leaflets of the native
r prosthetic valves in 248 patients, and surgery consisted of
imple valve replacement with mechanical or bioprosthetic
eart valves or valve repair. The infection had extended into the
nnulus and surrounding structures in 135 patients, and surgery
as complicated and involved radical resection of all infected
issues; reconstruction of the annulus with fresh autologous
ericardium, glutaraldehyde-fixed bovine pericardium, or Da-
ron fabric; and valve replacement. The techniques for these
adical procedures have been described in detail in previous
ublications.3-5 Twelve attending surgeons performed the op-
rations. Table 2 summarizes the operative data.
ollow-up
atients were seen annually by the referring cardiologist, and
ata were collected prospectively. Our research personnel ver-
fied all cardiac events. The mean follow-up was 6.1  5.2
ears; follow-up extended from 0 to 25 years and was complete.
tatistical Analysis
ll data analyses were performed with SAS 8.1 Software (SAS
nstitute, Inc, Cary, NC). Categorical variables are reported as
requencies, and all continuous variables are reported as mean 
Abbreviations and Acronyms
CI  confidence interval
HR hazard ratio
OR odds ratioD. Statistical comparison between certain subgroups was tested r
The Journal of Thoracicith unpaired t-test or nonparametric Wilcoxon test for continuous
ariables and 2 test or Fisher exact test for categorical variables.
he Kaplan–Meier method was used to calculate estimates for
ong-term survival or freedom from morbid events. The differ-
nces in longitudinal outcomes of native and prosthetic valve
ndocarditis were evaluated by using the log-rank statistic. The
ollowing perioperative variables were submitted to the multiva-
iable model for Cox regression analysis to determine the inde-
endent multivariable predictors operative and late mortality: pa-
ient age by increments of 5 years, sex, atrial fibrillation, functional
lass, shock, renal failure, diabetes, recent stroke, previous valve
urgery, coronary artery disease, left ventricular ejection fraction
ess than 40%, valve infected, paravalvular abscess, S aureus
nfection, timing of surgery, and type of valve implanted. Variable
ABLE 1. Clinical characteristics of 383 patients with ac-
ive infective endocarditis
haracteristic No. (%)
ge (y, mean  SD) 51  16
ale 247 (64)
lectrocardiogram
Sinus rhythm 318 (83)
Atrial fibrillation 54 (14)
Complete heart block 11 (3)
ssociated diseases
Diabetes mellitus 44 (11)
Hypertension 76 (20)
Chronic obstructive lung disease 13 (3)
Renal failure 42 (11)
Recent myocardial infarction (30 d) 11 (3)
Recent transient ischemic attack or stroke (30 d) 46 (12)
ew York Heart Association functional class
I 17 (4)
II 11 (3)
III 32 (9)
IV 322 (84)
ardiogenic or septic shock 53 (14)
ative valve endocarditis 266 (69)
Aortic valve 94 (35)
Mitral valve 77 (29)
Aortic and mitral valves 74 (28)
Aortic and other valves 9 (3)
Tricuspid valve 11 (4)
Pulmonary valve 1 (1)
revious cardiac surgery 129 (34)
rosthetic valve endocarditis 117 (31)
Aortic valve 66 (56)
Mitral valve 32 (27)
Aortic and mitral valves 18 (15)
Pulmonary valve 1 (1)
eft ventricular ejection fraction 40% 43 (11)
oronary artery disease 50 (13)
iming of surgery
Same hospitalization 206 (54)
Urgent or emergency 177 (46)etention criteria in the model were set at a P value of .05.
and Cardiovascular Surgery ● Volume 133, Number 1 145
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CDesults
here were 45 operative deaths. Cause of deaths was often
ultifactorial, but the main reasons were multiorgan failure
n 12 patients, low cardiac output syndrome in 8, intractable
epsis in 5, coagulopathy in 5, technical errors in 4, stroke
n 4, pulmonary embolism in 2, acute myocardial infarction
n 1, ruptured aortic root in 1, valve dehiscence in 1,
etroperitoneal bleeding in 1, and right ventricular failure in
. Table 3 shows the operative mortalities in various sub-
roups of patients. The operative mortality did not change
uring the period of study. Cox regression analysis identi-
ed preoperative shock (odds ratio [OR] 5.8, 95% confi-
ence interval [CI] 2.5-13.6), prosthetic valve endocarditis
OR 3.6, 95% CI 1.6-8.0), S aureus (OR 2.6, 95% CI
.1-6.0), and paravalvular abscess (OR 2.3, 95% CI 1.3-4.2)
s independent predictors of operative mortality.
Postoperative complications were common: 35 patients
equired reexploration of the chest for bleeding or tampon-
de; 20 patients had new strokes (14 intraoperative and 6
ostoperative), 54 patients required permanent pacemaker
or heart block, 20 required hemodialysis for new postop-
rative renal failure, and 2 had deep sternal infection de-
elop. In addition, 6 patients required further valve surgery
or valve dehiscence or persistent sepsis.
Eighty-eight patients died during the follow-up. The
auses of deaths were cardiac in 51 patients (congestive
eart failure in 14, recurrent endocarditis in 16, sudden
ardiac death in 8, myocardial infarction in 7, stroke in 4,
nd anticoagulation-related hemorrhage in 2), noncardiac in
ABLE 2. Operative data
perations performed
Aortic valve replacement 160
Mitral valve replacement 93
Mitral valve repair 16
Aortic valve replacement and mitral valve replacement 75
Aortic valve replacement and mitral valve repair 26
Tricuspid valve replacement 11
Pulmonary valve replacement 2
ypes of valves used
Mechanical 214
Bioprosthetic 133
Aortic homograft 18
Pulmonary homograft 2
Isolated mitral valve repair 16
dditional procedures
Bentall procedure 40
Supracoronary replacement of ascending aorta 8
Reconstruction of left ventricular outflow tract 42
Reconstruction of mitral annulus 49
Repair of congenital ventricular septal defect 19
Repair of left ventricular aneurysm 2
Coronary artery bypass grafting 512, and unknown in 5. The 15-year survivals were 44% 
46 The Journal of Thoracic and Cardiovascular Surgery ● Janu% for all patients, 59% 5% for patients with native valve
ndocarditis, and 25%  7% for patients with prosthetic
alve endocarditis (P  .001). Figure 1 compares the sur-
ivals of patients with native and prosthetic valve endocar-
itis. Cox regression analysis identified age by 5-year in-
rement (hazard ratio [HR] 1.15, 95% CI 1.07-1.24),
rosthetic valve endocarditis (HR 1.8, 95% CI 1.2-2.7), left
entricular ejection fraction less than 40% (HR 1.8, 95% CI
.1-2.7), recurrent endocarditis (HR 2.2, 95% CI 1.2-3.9),
nd shock (HR 2.5, 05% CI 1.6-4.0) as independent predic-
ors of death from all causes.
Recurrent endocarditis occurred 34 times in 32 patients:
0 during the first postoperative year and 22 in subsequent
ears. The offending microorganism was the same as in the
rst infection in 8 instances, different in 22, and culture
ABLE 3. Operative mortalities in various subgroups
ariable No.
Operative
mortality (%)
P
value
ative valve endocarditis 266 8.6
rosthetic valve endocarditis 117 18.8 .004
rosthetic valve endocarditis
Early (1 y) 39 25.6
Late 78 15.4 .033
reoperative shock 53 35.8 .001
aravalvular abscess 135 15.5 .054
taphylococcus aureus 87 17.2 .070
reoperative renal failure 42 26.2 .002
ecent transient ischemic
ttack or stroke
45 16 .112
jection fraction 40% 43 14 .095
iming of surgery
Same hospitalization 206 7.8
Urgent or emergency 177 16.4 .003
alve infected
Aortic valve 160 10
Mitral valve 109 11
Aortic and mitral valves 92 14
Other valves 22 18 .145
igure 1. Long-term survival of patients with native and pros-
hetic valve endocarditis.ary 2007
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CDegative in 4. Ten patients were operated on (2 patients had
reoperations each), with 1 death, and 22 patients were
reated with antibiotics alone, with 15 deaths. Figure 2
hows the freedom from recurrent infective endocarditis for
ll patients. The 15-year freedoms from recurrent endocar-
itis were 86%  3% for all patients, 84%  4% for
atients who had surgery for native valve endocarditis, and
0%  4% for those with prosthetic valve endocarditis (P
.39). The type of valve implanted had no effect on the
isk of recurrent endocarditis.
There were 36 reoperations in 34 patients: 12 for bio-
rosthetic valve failure, 12 for recurrent infective endocar-
itis, 7 for valve dehiscence without endocarditis, 2 for
ecurrent mitral regurgitation after mitral valve repair, 1 for
echanical valve dysfunction, 1 for a false aneurysm of the
ortic root, and 1 for aortic dissection. Figure 3 shows the
reedom from reoperation for all patients. The 15-year free-
oms from reoperation were 70%  6% for all patients,
6%  7% for patients with native valve endocarditis, and
4% 5% for patients with prosthetic valve endocarditis (P
.55).
Other valve-related complications were primary tissue
ailure of bioprosthetic valves in 12 patients, prosthetic
igure 2. Freedom from recurrent infective endocarditis for all
atients.
Figure 3. Freedom from reoperation for all patients.
o
The Journal of Thoracicalve dehiscence in 12, thromboembolism in 22, and major
nticoagulation-related hemorrhage in 3.
At the latest follow-up contact, 216 patients were alive
nd free from reoperation: 160 (74%) were in New York
eart Association functional class I, 35 (16%) were in class
I, and 21 (10%) were in class III.
iscussion
his report describes the early and late outcomes of surgery
or active infective endocarditis in a large cohort of patients
uring a 27-year interval. Although we are aware of a few
atients with disease deemed inoperable during this period,
heir number was very small. Indeed, in our series, 14% of
he patients were moribund when taken to the operating
heater. Thus the operative mortality and morbidity in this
eport probably reflect an accurate risk of surgery in patients
ith active infective endocarditis in a large tertiary care
ospital.
The operative mortality for active infective endocarditis
id not change during the past two decades in our institu-
ion. A stepwise logistic regression analysis identified pre-
perative shock, prosthetic valve endocarditis, paravalvular
bscess, and endocarditis caused by S aureus as independent
redictors of operative mortality. Thus to reduce operative
ortality, these variables would have to be modified, al-
hough this would not be always possible. For instance,
ost of our patients were treated initially in other hospitals,
nd we had no input regarding the medical management.
hey were referred for surgery only after medical therapy
ailed; often they were in intractable heart failure, and
ometimes they had multiorgan dysfunction. Although car-
iac surgery is necessary in fewer than a third of patients
ho have infective endocarditis of native valves and fewer
han half of those with prosthetic valves,6-9 a multidisci-
linary approach is necessary to treat these patients and
ust involve at least specialists in infectious disease, car-
iology, and cardiac surgery.10 The indications for and
iming of surgery are still controversial among internists
ho treat these patients, and the input of a cardiac surgeon
s needed if mortality and morbidity are to be reduced.10,11
lose surveillance of these patients is indispensable to de-
ect early failure of adequate antibiotic therapy to avoid
ardiogenic or septic shock and multiorgan failure.
It has been shown that cases of endocarditis caused by S
ureus and other virulent microorganisms on valves in the
eft side of the heart are best treated with early surgery.10-12
n a large merged database on native valve endocarditis, the
verall mortality was higher among patients with S aureus
ndocarditis than among those with other bacteria (20% vs
2%, P  .001); surprisingly, however, fewer patients in-
ected with S aureus had surgery (26% vs. 39%, P 
001).12 S aureus emerged as an independent predictor of
perative mortality in our surgical series. The operative
and Cardiovascular Surgery ● Volume 133, Number 1 147
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CDortality among patients with S aureus endocarditis was
7%, whereas that for all other bacteria was 10%.
The outcomes of prosthetic valve endocarditis are worse
han those of native valve endocarditis.9-11 We found that
ot only was prosthetic valve endocarditis associated with
igher operative mortality, but also it adversely affected
ong-term survival relative to native valve endocarditis. The
perative mortality for prosthetic valve endocarditis was
7.5% in our series. The mortalities in published series have
aried widely. In a report from the United Kingdom Heart
alve Registry on 322 cases of prosthetic valve endocardi-
is, the 30-day mortality was 20% and the 5- and 10-year
urvivals were 55% and 37%, respectively.13 Investigators
rom the Cleveland Clinic reported an operative mortality of
3% among 146 patients with prosthetic valve endocarditis;
mong those who survived surgery, the 5-year survival was
2% and the freedom from reoperation was 75%.14 In
nother report from the same institution on prosthetic aortic
alve endocarditis treated exclusively with aortic valve ho-
ograft, the operative mortality was only 3.9% and the 5-
nd 10-year survivals were 73% and 56%, respectively.15
The main reason the operative mortality for prosthetic
alve endocarditis is higher than that for native valve en-
ocarditis is the complexity of the operation and the fact
hat it is often associated with paravalvular abscess. Resec-
ion of aortic root abscess is indeed a complex operation, but
esection of mitral annulus abscess can be even worse.2-5
lthough aortic valve homografts are believed to be the best
alve for aortic root abscess,15,16 they are not a substitute
or radical débridement and implantation of the new valve
n healthy and strong tissues.2 Persistent or early recurrent
ndocarditis is probably related more to the surgeon’s rec-
gnition of and ability to extirpate all infected tissues than
o the type of valve used for replacement.2 We believe that
ortic homograft is ideally suited for reconstruction of the
ortic root, however, because it is easier to handle than
rosthetic materials and its anterior leaflet of the mitral
alve can be used to patch defects created by the resection
f the abscess. Although there is a lot of information on
urgery for aortic root abscess,15,16 there is little on mitral
nnulus abscess or on patients with combined mitral and
ortic valve abscesses.2,17,18 Resection of abscess in the
osterior mitral annulus, in the intervalvular fibrous body,
r both is a formidable operative procedure associated with
igh operative mortality, but we believe that it is the only
ay to eradicate the infection and provide satisfactory long-
erm results.3,19
Some surgeons believe that aortic valve homograft may
educe operative mortality and risk of reinfection in aortic
alve endocarditis.15-17 Others question its superiority.2,20
he reality is that valve homograft is seldom used in mitral
alve endocarditis17 and is not used in aortic valve endo-
arditis as frequently as are mechanical and bioprosthetic
48 The Journal of Thoracic and Cardiovascular Surgery ● Janualves in most series.6,13,14,20,21 The risk of recurrent endo-
arditis is similar for mechanical and bioprosthetic valves.21
iven the complexity of some of these operations, we tend
o use more mechanical than bioprosthetic valves, particu-
arly in younger patients.
Despite perioperative problems in treating patients with
nfective endocarditis, the long-term survival is satisfactory,
articularly for patients with native valve endocarditis. The
5-year survival in our series was 59%, similar to that
eported by Stanford University.21 The 15-year survival
mong patients with prosthetic valve endocarditis was only
5%, also similar to that of Stanford University.21 The
easons for the differences in long-term survival between
ative and prosthetic valve endocarditis are likely multifac-
orial and include higher operative mortality, more complex
perations, and such patient variables as older age and
orse ventricular function.
The rates of reoperation among patients who undergo
urgery for active infective endocarditis appear to be only
lightly higher than those among patients with prosthetic
alves who never had endocarditis, but the rates of recurrent
nfection are significantly increased. This suggests that a
redisposing factor in addition to the prosthetic valve plays
role in the development of endocarditis in certain
atients.22,23
In conclusion, surgery for active infective endocarditis
ontinues to be challenging and to be associated with high
perative mortality and morbidity. The long-term survival is
atisfactory, although these patients are at higher risk for
evelopment of recurrent endocarditis than are patients who
ave never had valve infection.
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iscussion
r Steven W. Guyton (Seattle, Wash). Thank you, Dr Gavra, for
n excellent presentation and for the opportunity to review your
anuscript before the meeting.
Active endocarditis that cannot be managed with antibiotic
herapy alone is a devastating problem, as you have so well
llustrated. You might illustrate this as well by including a graph
ndicating the freedom from mortality and morbidity—reoperation,
ecurrent endocarditis, thromboembolism, stroke, heart block, re-
al failure, sternal infection, and others. I anticipate that close to
00% of your patients will show complications during your 10- to
5-year follow-up. I agree with your emphasis on aggressive
ébridement of all infected tissue and less emphasis on the type of
rosthesis. The prostheses you used were approximately 2:1 me-
hanical versus bioprosthetic and then some homografts. Have you
een a difference in outcomes depending on your choice of pros-
hesis, and what is your preference at present?
The Journal of ThoracicDr Gavra. I am not the senior surgeon, but I can assure you
hat Dr David’s approach is to excise all infected tissues to
llow implantation of a prosthetic valve in healthy and strong
issues. He believes that the outcomes for patients with para-
alvular abscess is influenced more by the surgeon’s ability to
ecognize and extirpate all infected tissue than by the type of
rosthetic valve implanted.
Dr Guyton. Did you look at the outcomes, though, related to
he type of prosthesis that was used as to whether your data
howed any difference?
Dr Gavra. No.
Dr Guyton. Recurrent endocarditis treated medically had a
ismal prognosis, with a 75% mortality reported in the manuscript.
omografts have been touted as more resistant to recurrent infec-
ion. Is this an argument for the use of homografts?
Dr Gavra. With respect to the patients who had recurrent
ndocarditis, I’d have to say that the 22 patients who were treated
ith antibiotics only were treated elsewhere, not in Toronto Gen-
ral Hospital and they didn’t benefit from surgery. I would suppose
his to be one of the reasons that mortality is so high for this
ubgroup of endocarditis.
Dr Guyton. Thank you for that clarification. Ten percent of
our patients were operated on for large vegetations. This is the
rst time I have seen this as an indication for surgery from your
roup. Why were operations performed for vegetation size? I know
y cardiologists get skittish about these vegetations, but I’ve not
een convinced that operating for the size of vegetations is appro-
riate.
Dr Gavra. Because of fear of embolization, vegetations larger
han 10 mm in diameter were considered an indication for surgery.
Dr Guyton. I think we might want to be very careful about
sing that as an indication for surgery. In the medical literature,
here is encouragement for shorter durations of antibiotic treat-
ent, which I have found disturbing in this population of patients
iven the consequences of treatment failure. I note that you re-
orted freedom from recurrent endocarditis to be better after
rosthetic valve endocarditis. Were these patients treated differ-
ntly because they already had prosthetic valves, and what is your
tandard course of antibiotic therapy?
Dr Gavra. The patients in this study received intravenous
ntibiotics for a total of 6 weeks. Although my slide showed a
ower risk of recurrent endocarditis among patients with prosthetic
alve than in those with native valve endocarditis, the difference
as not statistically significant.
Dr Guyton. In S aureus infection timing of operation is im-
ortant. As a tertiary referral center, you did not always have
ontrol over when the operation occurred relative to the date of
resentation. In analyzing the data, did you find a difference in
utcomes depending on when the patient was operated on versus
he time of presentation?
Dr Gavra. Although the overall mortality among patients with
aureus endocarditis was higher than that among those with other
acteria, I don’t know whether timing of surgery played a role in
he outcome.
Dr Guyton. Having that analysis might help us evaluate the
ata a little bit more extensively. Thank you for opportunity to
eview the manuscript and to discuss this presentation.Dr Gavra. Thank you very much, Dr Guyton.
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